Sanofi Genzyme hit with patent lawsuit over new eczema drug

Sanofi Genzyme ’s next potential blockbuster treatment is running into legal trouble in California, where a unit of Amgen has accused the Cambridge rare disease drugmaker of infringing one of its patents. Immunex Corp., a subsidiary of Amgen (Nasdaq: AMGN), filed a complaint in Los Angeles federal court on Apri l 5 claiming that an eczema drug developed by Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals (Nasdaq: REGN) infringes a patent related to a failed asthma treatment. Analysts have said…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news